Egypt’s Hepatitis C Program: A Model for Africa’s Health Initiatives

By Crystal Lubbe

December 12, 2024

The article from the Africa CDC website, titled “Egypt’s Hepatitis Programme Becomes a Model for African Countries,” highlights Egypt’s successful hepatitis C elimination program, which serves as a benchmark for other African countries. By implementing the “100 Million Healthier Lives” campaign, Egypt has achieved Gold-tier certification for its progress toward eliminating hepatitis C, as recognised by the World Health Organization (WHO). This remarkable achievement showcases how effective public health initiatives can lead to significant health improvements across the continent.

Egypt’s Hepatitis C Elimination Program

Egypt Hepatitis C Program has benefited its citizens and set a powerful example for other African nations. Notably, the country has made significant strides in training and capacity building.

Training and Capacity Building

The Africa CDC, in collaboration with Egypt’s Ministry of Health and Population, has implemented training programs for experts from various African Union member states. These programs are designed to equip participants with the necessary skills to launch “screen-and-treat” programs for hepatitis C. To date, 26 members have been trained, with an additional cohort of 31 participants from multiple African countries completing their training in November 2024.

Regional Collaboration and Support

Moreover, Egypt plays a pivotal role by providing technical support, screening software, and free treatment for one million people in 14 African nations. This collaborative effort aligns with WHO screening and treatment guidelines.

Best Practices and Challenges

The training includes lectures, field trips, and discussions on best practices and challenges in hepatitis elimination. Participants visit hospitals, healthcare settings, and pharmaceutical companies to understand Egypt’s comprehensive strategy.

Africa CDC’s Role

The Africa CDC is actively supporting African nations by funding seroprevalence surveys, providing necessary kits and drugs, and training health workers. For example, Madagascar is currently undergoing a capacity and readiness assessment for viral hepatitis elimination, as part of the support provided by the Africa CDC.

South-South Cooperation

The initiative promotes South-South cooperation, encouraging shared learning and collaboration to improve public health outcomes continent-wide. This approach is a cornerstone of Egypt’s hepatitis C elimination successes and its potential replicability in other African countries.

Action Plans and Future Initiatives

Country representatives create action plans to apply training and identify needed support from Africa CDC and Egypt. For example, Cameroon is poised to launch a Triple elimination strategy, guided by the training and support it has received.

Conclusion

Egypt Hepatitis C Program stands as a model for other African countries. Notably thanks to its comprehensive approach, innovative financing, and political commitment. The program’s achievements signal a promising pathway toward the global goal of eliminating viral hepatitis by 2030. With continued regional collaboration and strong action plans, the impact of Egypt’s efforts will undoubtedly resonate across the continent.

Reference url

Recent Posts

CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth

By HEOR Staff Writer

September 17, 2025

What makes the CAPVAXIVE pneumococcal vaccine significant for children and adolescents at higher risk for pneumococcal disease? The CAPVAXIVE pneumococcal vaccine (21-valent conjugate vaccine) demonstrated robust immune responses and broad serotype coverage in Merck’s Phase 3 STRIDE-13 trial. ...
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks

By HEOR Staff Writer

September 16, 2025

Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabetes with proven cardiovascular benefits. This deci...
New Federal Actions to Combat Misleading Prescription Drug Ads in 2025

By João L. Carapinha

September 11, 2025

Misleading prescription drug ads have become a pressing concern in the United States, prompting decisive federal action. What are the new measures targeting deceptive pharmaceutical advertising, and how will these changes affect public health and healthcare costs? In September 2025, a